| Style | Citing Format |
|---|---|
| MLA | Merat S, et al.. "Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial." Clinical Infectious Diseases, vol. 70, no. 10, 2020, pp. 2206-2212. |
| APA | Merat S, Sharifi AH, Poustchi H, Hajiani E, Gharavi A, Karimi J, Mansourghanaei F, Fattahi MR, Ahmadi L, Somi MH, Kalantari H, Ghadir MR, Sheikhesmaeili F, Baniasadi N, Sohrabi M, Moosavy S, Ziaee M, Zahedi MJ, Mokhtare M, ... Malekzadeh R (2020). Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial. Clinical Infectious Diseases, 70(10), 2206-2212. |
| Chicago | Merat S, Sharifi AH, Poustchi H, Hajiani E, Gharavi A, Karimi J, Mansourghanaei F, et al.. "Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial." Clinical Infectious Diseases 70, no. 10 (2020): 2206-2212. |
| Harvard | Merat S et al. (2020) 'Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial', Clinical Infectious Diseases, 70(10), pp. 2206-2212. |
| Vancouver | Merat S, Sharifi AH, Poustchi H, Hajiani E, Gharavi A, Karimi J, et al.. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial. Clinical Infectious Diseases. 2020;70(10):2206-2212. |
| BibTex | @article{ author = {Merat S and Sharifi AH and Poustchi H and Hajiani E and Gharavi A and Karimi J and Mansourghanaei F and Fattahi MR and Ahmadi L and Somi MH and Kalantari H and Ghadir MR and Sheikhesmaeili F and Baniasadi N and Sohrabi M and Moosavy S and Ziaee M and Zahedi MJ and Mokhtare M and Sali S and Sayad B and Afshar B and Bakhshipour A and Parsi A and Sharifian A and Amiriani T and Malekzadeh Z and Merat D and Ganji A and Rahmanisamani F and Jamali R and Sofian M and Ghezlou M and Sohrabpour AA and Goshayeshi L and Valizadehtoosi SM and Eslami L and Maleki I and Hormati A and Shayesteh AA and Shayesteh E and Norouzi A and Abna Z and Janbakhsh A and Fakheri H and Minakari M and Sardarian H and Ghajary AF and Fattahiabdizadeh M and Latifnia M and Roozbeh F and Agah S and Fakhriehasl S and Nateghibaygi A and Fattahi B and Nateghibaygi H and Hill A and Malekzadeh R}, title = {Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial}, journal = {Clinical Infectious Diseases}, volume = {70}, number = {10}, pages = {2206-2212}, year = {2020} } |
| RIS | TY - JOUR AU - Merat S AU - Sharifi AH AU - Poustchi H AU - Hajiani E AU - Gharavi A AU - Karimi J AU - Mansourghanaei F AU - Fattahi MR AU - Ahmadi L AU - Somi MH AU - Kalantari H AU - Ghadir MR AU - Sheikhesmaeili F AU - Baniasadi N AU - Sohrabi M AU - Moosavy S AU - Ziaee M AU - Zahedi MJ AU - Mokhtare M AU - Sali S AU - Sayad B AU - Afshar B AU - Bakhshipour A AU - Parsi A AU - Sharifian A AU - Amiriani T AU - Malekzadeh Z AU - Merat D AU - Ganji A AU - Rahmanisamani F AU - Jamali R AU - Sofian M AU - Ghezlou M AU - Sohrabpour AA AU - Goshayeshi L AU - Valizadehtoosi SM AU - Eslami L AU - Maleki I AU - Hormati A AU - Shayesteh AA AU - Shayesteh E AU - Norouzi A AU - Abna Z AU - Janbakhsh A AU - Fakheri H AU - Minakari M AU - Sardarian H AU - Ghajary AF AU - Fattahiabdizadeh M AU - Latifnia M AU - Roozbeh F AU - Agah S AU - Fakhriehasl S AU - Nateghibaygi A AU - Fattahi B AU - Nateghibaygi H AU - Hill A AU - Malekzadeh R TI - Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial JO - Clinical Infectious Diseases VL - 70 IS - 10 SP - 2206 EP - 2212 PY - 2020 ER - |